NEW YORK, Feb. 11, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Fifth Street Asset Management Inc. common stock (NASDAQ:FSAM) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with FSAM’s October 30, 2014 initial public offering (the “IPO”) of the important March 7, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for FSAM investors under the federal securities laws.
To join the FSAM class action, go to the firm’s website at http://rosenlegal.com/cases-815.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, the offering documents filed in connection with the IPO contained materially false and misleading statements and omissions, including that: (1) FSAM had $4.2 billion in assets under management from affiliated company, Fifth Street Finance Corp. (“FSC”), as of June 30, 2014 when in fact a material portion of FSC’s portfolio was impaired and should have been placed on non-accrual prior to the IPO; (2) FSAM’s purportedly “strong growth in assets under management” and “outstanding investor performance” was fueled in part by delaying the write down of impaired investments in FSC’s portfolio; and (3) FSC had a material weakness in its controls over financial reporting. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-815.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



